Skip to main content
2025 ACVIM Forum Main banner
Icon Legend
This session is not on your agenda.
This session is on your agenda. Click again to remove it.
Presentation Icons
ACVIM Resident Research Award Eligible
ACVIM Resident Research Award Eligible
Additional Fees May Be Required
Additional Fees May Be Required
By Invite Only
By Invite Only
Capturing for On Demand
Capturing for On Demand
Cardiology Research Abstract Award Eligible
Cardiology Research Abstract Award Eligible
ERC Approved Lecture for ACVIM Residency
ERC Approved Lecture for ACVIM Residency
Poster
Poster
Livestream
Livestream
One Health
One Health
Pre-Registration Required
Pre-Registration Required
Research Abstract
Research Abstract
Specialty Symposium
Specialty Symposium
ACVIM Resident Research Award Winner
ACVIM Resident Research Award Winner
Cardiology Research Abstract Award Winner
Cardiology Research Abstract Award Winner
Back
ViewAttendees 13

Small Animal Internal Medicine

In Person Only

FIP Expert Update: Current Status After A Year of Legal Therapy in the USA

Thursday, June 19, 2025
4:30 PM – 6:00 PM ET
Location: KICC M107
Pending CE: 1.5 Medical
Disclosure(s):
Samantha Evans, DVM, PhD, DACVP: No financial relationships to disclose
Petra Cerna, PhD, DACVIM (SAIM), MANZCVS (Medicine of Cats): No relevant disclosure to display
Sally J. Coggins, BVSc (Hons I), PhD, MANZCVS (Medicine of Cats): No relevant disclosure to display
Krystle L. Reagan, DVM, PhD, DACVIM (SAIM): No financial relationships to disclose
Presentation Description / Summary: This session will bring together four FIP researchers and experts who regularly advise DVMs around the globe on treatment of feline infectious peritonitis (FIP) in cats. This field continues to evolve rapidly and this session aims to update participants on the latest scientific evidence available in this field. We will review the status of therapy in the USA after one year of legally-prescribable GS-441524 through compounding pharmacies (which began on June 1st of 2024). We will provide updates on newly available diagnostics for FIP and review key treatment and monitoring literature published in the past 12 months, inducing when it is appropriate to shorten treatment duration based on newly available research. We will also discuss the recent (September 2024) release of legally-prescribable molnupiravir in the USA, an overview of the protocols for all antiviral compounds available, and when to choose which drug. Finally, we will highlight emerging evidence on comorbidities to FIP like IMHA and sepsis.

Learning Objectives:

  • Efficiently and effectively treat FIP in cats based on the latest scientific evidence.
  • Make confident therapeutic decisions surrounding drug choice, dosage, and treatment duration for FIP.
  • Manage IMHA and sepsis as comorbidities to FIP.